Authors:
GANDARA DR
LARA P
CADMAN T
LAU D
UHRICH M
TURRELL C
MORGAN R
DIMERY I
EDELMAN M
PEREZ EA
SYNOLD T
DOROSHOW J
MUGGIA F
DEGREGORIO M
Citation: Dr. Gandara et al., HIGH-DOSE TOREMIFENE AS A CISPLATIN MODULATOR - TARGETED PLASMA-LEVELS ARE ACHIEVABLE CLINICALLY, Journal of investigative medicine, 46(1), 1998, pp. 148-148
Authors:
OLEARY JJ
SHAPIRO RL
REN CJ
CHUANG N
COHEN HW
MUGGIA F
POTMESIL M
Citation: Jj. Oleary et al., ANTI-ANGIOGENIC EFFECTS OF 9-AMINO-20(S)-CAMPTOTHECIN (9AC), TOPOTECAN (TTN), AND CAMPTOSAR (CPT-11), Annals of oncology, 9, 1998, pp. 296-296
Authors:
LARA PN
GANDARA DR
WURZ GT
LAU D
UHRICH M
TURRELL C
RASCHKO J
EDELMAN MJ
SYNOLD T
DOROSHOW J
MUGGIA F
PEREZ EA
DEGREGORIO M
Citation: Pn. Lara et al., HIGH-DOSE TOREMIFENE AS A CISPLATIN MODULATOR IN METASTATIC NONSMALL CELL LUNG-CANCER - TARGETED PLASMA-LEVELS ARE ACHIEVABLE CLINICALLY, Cancer chemotherapy and pharmacology, 42(6), 1998, pp. 504-508
Authors:
FORMENTI SC
DUNNINGTON G
UZIELI B
LENZ H
KERENROSENBERG S
SILBERMAN H
SPICER D
DENK M
LEICHMAN G
GROSHEN S
WATKINS K
MUGGIA F
FLORENTINE B
PRESS M
DANENBERG K
DANENBERG P
Citation: Sc. Formenti et al., ORIGINAL P53 STATUS PREDICTS FOR PATHOLOGICAL RESPONSE IN LOCALLY ADVANCED BREAST-CANCER PATIENTS TREATED PREOPERATIVELY WITH CONTINUOUS-INFUSION 5-FLUOROURACIL AND RADIATION-THERAPY, International journal of radiation oncology, biology, physics, 39(5), 1997, pp. 1059-1068
Authors:
ROBERTS JA
KUDELKA AP
SPRIGGS DR
MUGGIA F
LURAIN J
GROVE W
KOWAL C
Citation: Ja. Roberts et al., A PHASE-2 STUDY OF CISPLATIN ANALOG CI-973 IN THE TREATMENT OF PATIENTS WITH REFRACTORY, ADVANCED OVARIAN-CANCER, International journal of gynecological cancer, 6(4), 1996, pp. 257-260
Authors:
DOUER D
LEVINE A
ANDERSON WF
GORDON M
GROSHEN S
KHAN A
MOHRBACHER A
MUGGIA F
SHIBATA D
Citation: D. Douer et al., HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW PLUS PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION FOR PATIENTS WITH LYMPHOMA OR METASTATIC BREAST-CANCER - USE OF MARKER GENES TO INVESTIGATE HEMATOPOIETIC RECONSTITUTION IN ADULTS, Human gene therapy, 7(5), 1996, pp. 669-684
Authors:
LI WY
CHATTERJEE DJ
SHETTY BV
WU EY
MUGGIA F
KODA RT
Citation: Wy. Li et al., HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC METHOD FOR THE DETERMINATION OF A NOVEL THYMIDYLATE SYNTHASE INHIBITOR, AG-331, IN HUMAN SERUM, Journal of chromatography B. Biomedical applications, 673(2), 1995, pp. 281-288
Authors:
GILL PS
ESPINA BM
MUGGIA F
CABRIALES S
TULPULE A
ESPLIN JA
LIEBMAN HA
FORSSEN E
ROSS ME
LEVINE AM
Citation: Ps. Gill et al., PHASE I II CLINICAL AND PHARMACOKINETIC EVALUATION OF LIPOSOMAL DAUNORUBICIN/, Journal of clinical oncology, 13(4), 1995, pp. 996-1003
Authors:
UZIELY B
GROSHEN S
JEFFERS S
MORRIS M
RUSSELL C
ROMAN L
MUDERSPACH L
MUGGIA F
Citation: B. Uziely et al., PACLITAXEL (TAXOL) IN HEAVILY PRETREATED OVARIAN-CANCER - ANTITUMOR-ACTIVITY AND COMPLICATIONS, Annals of oncology, 5(9), 1994, pp. 827-833
Citation: B. Uziely et al., LOW-DOSES OF DEXAMETHASONE PROTECT AGAINST PACLITAXEL (TAXOL)-RELATEDHYPERSENSITIVITY REACTIONS FOLLOWING CYCLE-1, Annals of oncology, 5(5), 1994, pp. 474-474
Citation: Jj. Zheng et al., PRECLINICAL PHARMACOKINETICS AND STABILITY OF ISOPHOSPHORAMIDE MUSTARD, Cancer chemotherapy and pharmacology, 33(5), 1994, pp. 391-398
Authors:
GUAGLIANONE P
CHAN K
DELAFLORWEISS E
HANISCH R
JEFFERS S
SHARMA D
MUGGIA F
Citation: P. Guaglianone et al., PHASE-I AND PHARMACOLOGICAL STUDY OF LIPOSOMAL DAUNORUBICIN (DAUNOXOME), Investigational new drugs, 12(2), 1994, pp. 103-110
Authors:
TOCKMAN MS
EROZAN YS
GUPTA P
PIANTADOSI S
MULSHINE JL
RUCKDESCHEL JC
BUKOWSKI RM
LAD T
ETTINGER DS
DESLAURIERS J
GINSBERG R
KELLY K
HOLMES EC
MUGGIA F
ROTH JA
JOHNSTON M
MCKNEALLY MF
Citation: Ms. Tockman et al., THE EARLY DETECTION OF 2ND PRIMARY LUNG CANCERS BY SPUTUM IMMUNOSTAINING, Chest, 106(6), 1994, pp. 190000385-190000390